[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546549":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":64,"collaborators":44,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":44,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":44,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":94,"whyStopped":44,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Nesta Clinic","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Progestin Primed Ovarian Stimulation (PPOS)","EXPERIMENTAL","In this patient group, progestin based protocol is going to be the main course of treatment.",[13],"Drug: Progestin",{"label":15,"type":16,"description":17,"interventionNames":18},"GnRH Antagonist Stimulation","ACTIVE_COMPARATOR","In this patient group, GnRH Antagonist treatment protocol is going to be the main course of treatment.",[19],"Drug: GnRH antagonist",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Progestin","In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag\u002FTurkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg\u002F0.5 mL, Merck Serono S.p.A., Bari\u002FItaly) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg\u002FmL, Ferring GmbH, Kiel\u002FGermany) 2 amp SC will be used. All oocytes picked-up will be frozen.",[9],[27],"Progestin Primed Ovarian Stimulation Protocol",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"GnRH antagonist","In this regimen, Cetrorelix (Cetrotide©, 250 mcg\u002FmL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg\u002F0.5 mL, Merck Serono S.p.A., Bari\u002FItaly) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg\u002FmL, Ferring GmbH, Kiel\u002FGermany) 2 amp SC will be used. All oocytes picked-up will be frozen.",[15],[33],"GnRH Antagonist Ovarian Stimulation Protocol",[35],{"name":36,"affiliation":37,"role":38},"Ercan Bastu, M.D.","Owner","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Zuhal Yucel, B.N.","CONTACT","+90 542 125 29 99",null,"zuhal.yucel@nestaclinic.com",[47],{"facility":5,"status":44,"city":48,"state":49,"zip":50,"country":51,"countryCode":44,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Istanbul","Sisli","34349","Turkey (Türkiye)",{"type":53,"coordinates":54},"Point",[55,56],28.94966,41.01384,{"lat":56,"lon":55},[59,60],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},{"name":61,"role":42,"phone":62,"phoneExt":44,"email":63},"Seyma Aydiner, B.B.A","+90 212 219 99 29","seyma.aydiner@nestaclinic.com",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"PRINCIPAL_INVESTIGATOR","Emre Kar","Principal Investigator","100546549","phase-4-comparison-of-progestin-primed-ovarian-stimulation-ppos-vsgnrh-antagonist-methods-on-ivf-outcomes-100546549",false,"NCT06396390","Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","The Comparative Results of Progestin Primed Ovarian Stimulation (PPOS) and GnRH Antagonist Ovarian Stimulation Methods on IVF Outcomes","Inclusion Criteria:\n\n* BMI \\> 18 kg\u002Fm2 ve \\\u003C35 kg\u002Fm2\n* Couples that accept being included in the study\n* Couple accepting thawed embryo transfer\n\nExclusion Criteria:\n\n* Known chromosomal abnormality in either member of the couple\n* Couples with unexplained infertility\n* BMI \\> 30 kg\u002Fm2\n* Mullerian malformations\n* Undergoing oocyte cryopreservation for medical reasons (such as malignancies)\n* Couple insists on fresh embryo transfer",true,"FEMALE","18 Years","45 Years",{"count":80,"type":81},152,"ESTIMATED","INTERVENTIONAL",[84],"PHASE4","The goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: Progestin Primed Ovarian Stimulation (PPOS) vs. GnRH Antagonist in embryologic outcomes of IVF Patients.",[87,88,89],"IVF","Fertility Issues","Infertility",[91,92,89,93],"GnRH Antagonist","Progestin Primed Ovarian Stimulation","Ovarian Stimulation","NOT_YET_RECRUITING","2024-07-15",{"date":97,"type":98},"2024-07-17","ACTUAL",{"date":100,"type":81},"2024-08-01",{"date":102,"type":81},"2026-08-01",{"name":5,"class":6},1]